Press release


24/05/2017
SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis.
SOM Biotech
SOM Biotech Ltd a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases, today announces an exclusive worldwide license agreement with U.S. based Corino Therapeutics, Inc. (Corino), for the clinical development and commercialization of SOM0226 (CRX-1008), a drug for the treatment of ATTR.
 
 
Documentación:
 
 
 
Permalink  
 
Developed by Web4Bio